Literature DB >> 11035547

Optic atrophy in association with cobalamin C (cblC) disease.

N Patton1, S Beatty, I C Lloyd, J E Wraith.   

Abstract

PURPOSE: To report the association of optic atrophy with cobalamin C (cblC) disease.
METHODS: Descriptive case reports on three patients, two of whom were siblings.
RESULTS: All three patients with cblC disease exhibited bilateral optic atrophy with decreased visual acuity. Of the two siblings, the younger sister had received cobalamin supplements from birth and the mother had been given cobalamin supplements prenatally.
CONCLUSION: These three cases confirm the association of optic atrophy with cblC disease. Early treatment with cobalamin supplements does not appear to prevent the development of optic atrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035547

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  13 in total

1.  Optic neuropathy in methylmalonic acidemia: the role of neuroprotection.

Authors:  Sergio Pinar-Sueiro; Ricardo Martínez-Fernández; Sergio Lage-Medina; Luis Aldamiz-Echevarria; Elena Vecino
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

Review 2.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 4.  Optic atrophies in metabolic disorders.

Authors:  Marjan Huizing; Brian P Brooks; Yair Anikster
Journal:  Mol Genet Metab       Date:  2005-09-27       Impact factor: 4.797

5.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

6.  Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

Authors:  Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

7.  Hydroxocobalamin dose escalation improves metabolic control in cblC.

Authors:  N Carrillo-Carrasco; J Sloan; D Valle; A Hamosh; C P Venditti
Journal:  J Inherit Metab Dis       Date:  2009-10-10       Impact factor: 4.982

8.  Propionic acidemia and optic neuropathy: a report of two cases.

Authors:  Carolina Arias; Erna Raimann; Pilar Peredo; Juan Francisco Cabello; Gabriela Castro; Alf Valiente; Alicia de la Parra; Paulina Bravo; Cecilia Okuma; Verónica Cornejo
Journal:  JIMD Rep       Date:  2013-07-02

9.  Clinical presentation and outcome in a series of 88 patients with the cblC defect.

Authors:  Sabine Fischer; Martina Huemer; Matthias Baumgartner; Federica Deodato; Diana Ballhausen; Avihu Boneh; Alberto B Burlina; Roberto Cerone; Paula Garcia; Gülden Gökçay; Stephanie Grünewald; Johannes Häberle; Jaak Jaeken; David Ketteridge; Martin Lindner; Hanna Mandel; Diego Martinelli; Esmeralda G Martins; Karl O Schwab; Sarah C Gruenert; Bernd C Schwahn; László Sztriha; Maren Tomaske; Friedrich Trefz; Laura Vilarinho; David S Rosenblatt; Brian Fowler; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2014-03-06       Impact factor: 4.982

10.  Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency.

Authors:  Brian P Brooks; Amy H Thompson; Jennifer L Sloan; Irini Manoli; Nuria Carrillo-Carrasco; Wadih M Zein; Charles P Venditti
Journal:  Ophthalmology       Date:  2016-01-26       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.